RespulesClinical Overview
Fluticasone Propionate Respules (0.5mg per 2ml) is an inhaled corticosteroid nebulizer suspension on the WHO Model List framework. Delivers high topical anti-inflammatory potency to bronchial mucosal tissues. Indicated for maintenance management of severe persistent asthma and acute exacerbations in pediatric and adult patients unable to coordinate inhaler devices.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Administer via a jet nebulizer equipped with a mouthpiece or suitable face mask over 10 to 15 minutes twice daily. Rinse mouth and wash face thoroughly after nebulization.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Oral candidiasis, hoarseness, throat irritation, facial skin irritation. Rare/Severe: Paradoxical bronchospasm.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Rinse mouth and wash face after treatment. For inhalation via nebulizer ONLY; do NOT inject or swallow.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, pulmonological diagnosis, or respiratory management recommendations. Inhalation therapies and allergy medications should be used strictly under the guidance of a qualified pulmonologist or registered medical practitioner.
Salmeterol 50mcg + Fluticasone 250mcg Rotacaps
Salmeterol Xinafoate (25mcg/50mcg) and Fluticasone Propionate (100mcg/250mcg/500mcg Inhaler, Rotacaps) is a benchmark inhaled corticosteroid and long-acting beta-2 agonist combination on the WHO Model List of Essential Medicines. Fluticasone exerts profound local anti-inflammatory, immunosuppressive, and anti-edematous effects in bronchial mucosa with low systemic bioavailability due to extensive first-pass metabolism. Salmeterol provides long-acting bronchodilation lasting over 12 hours via persistent beta-2 receptor activation. Indicated for maintenance therapy of persistent bronchial asthma and maintenance treatment of airflow obstruction in patients with severe COPD and recurrent exacerbations.
Azelastine Hydrochloride 140mcg + Fluticasone Propionate 50mcg Nasal Spray
Azelastine Hydrochloride (140mcg) and Fluticasone Propionate (50mcg) Nasal Spray is a fixed-dose second-generation H1-antihistamine and corticosteroid combination on the WHO Model List framework. Azelastine provides rapid-onset (within 15 minutes) blockade of histamine H1 receptors, relieving sneezing, nasal itching, and rhinorrhea. Fluticasone provides sustained 24-hour suppression of mucosal inflammation, relieving stubborn nasal congestion. Proven significantly superior to either monotherapy for Moderate-to-Severe Allergic Rhinitis and seasonal rhinoconjunctivitis.
Fluticasone Propionate Nasal Spray 50 mcg
Fluticasone Propionate / Fluticasone Furoate Nasal Spray (27.5mcg, 50mcg per spray) is a synthetic trifluorinated corticosteroid on the WHO Model List of Essential Medicines. It binds with exceptionally high affinity to glucocorticoid receptors in the nasal mucosa, inhibiting mediator release (histamine, leukotrienes, cytokines) with virtually negligible systemic oral bioavailability (<0.1%). Indicated for management of seasonal allergic rhinitis, perennial allergic rhinitis, and nasal polyposis.
Salmeterol 25mcg + Fluticasone Propionate 250mcg Inhaler
Salmeterol Xinafoate (25mcg/50mcg) and Fluticasone Propionate (100mcg/250mcg/500mcg Inhaler, Rotacaps) is a benchmark inhaled corticosteroid and long-acting beta-2 agonist combination on the WHO Model List of Essential Medicines. Fluticasone exerts profound local anti-inflammatory, immunosuppressive, and anti-edematous effects in bronchial mucosa with low systemic bioavailability due to extensive first-pass metabolism. Salmeterol provides long-acting bronchodilation lasting over 12 hours via persistent beta-2 receptor activation. Indicated for maintenance therapy of persistent bronchial asthma and maintenance treatment of airflow obstruction in patients with severe COPD and recurrent exacerbations.